In patients with atrial fibrillation (AF), concomitant coronary artery disease is often present. 1 Many uncertainties still exist about the concomitant use of antiplatelet and oral anticoagulation (OAC) therapy in this clinical setting, especially in AF patients undergoing percutaneous coronary intervention with stenting (PCI-S).
2 Indeed, a balance should be obtained between stroke prevention in AF (which requires OAC), stent thrombosis and recurrent cardiac ischemia (both requiring dual antiplatelet therapy) and serious bleeding (by combining OAC with antiplatelet therapy).
The use of triple antithrombotic therapy (TAT), namely aspirin, any P2Y12 inhibitor (i.e. clopidogrel, prasugrel, ticagrelor) and OAC with a vitamin K antagonist (VKA), is associated with a higher risk for serious bleeding, 3 despite targeting lower international normalized ratio (INR) values. 3 An increased risk of bleeding with TAT has been documented, in hospitalized AF patients 4 and in those following myocardial infarction (MI) or a PCI-S. 5 Major guidelines 6, 7 currently recommend initial TAT, even if only for a short period of time, followed by a period of single antiplatelet therapy plus OAC up to 12 months after PCI-S. In 2014, the joint European consensus document endorsed by the Heart Rhythm Society and Asia-Pacific Heart Rhythm Society on the management of AF patients presenting with an acute coronary syndrome or undergoing PCI-S was published, which recommended evaluation of thromboembolic (CHA 2 DS 2 -VASc score) and bleeding (HAS-BLED score) risks, followed by consideration of antithrombotic strategy based on presentation (acute vs. elective) and type of stent. 8 However, thromboembolic and bleeding risks with VKA are closely related to quality of anticoagulation control, as reflected by time in therapeutic range (TTR) within an INR 2.0-3.0. 9 The AFCAS registry was a prospective multicenter European registry including AF patients undergoing PCI-S. Baseline and 1-year outcomes from AFCAS have been previously published. 10, 11 The objective of this ancillary study from AFCAS was to relate major adverse outcomes, primarily major bleeding, in AF patients prescribed TAT after a PCI-S to quality of anticoagulation control, as reflected by TTR. Secondary outcomes were cardiovascular/cerebrovascular events.
Methods
The AFCAS registry was an observational, prospective, multicentre study about the clinical management of AF patients undergoing PCI-S. In brief, all AF patients referred for a PCI-S procedure were eligible to take part in the study. A 12-months follow-up observation period was planned in order to record all major adverse outcomes. For this study, all patients prescribed TAT at discharge after the PCI-S procedure with complete data about clinical characteristics, follow-up observation and available data about TTR throughout the study follow-up period were analyzed.
Thromboembolic risk was categorized according to CHA 2 DS 2 -VASc score.
12 "Low risk" patients were defined as males with a CHA 2 DS 2 -VASc = 0 or females with CHA 2 DS 2 -VASc =1; "moderate risk" was defined as male patients with CHA 2 DS 2 -VASc = 1; and "high risk" with CHA 2 DS 2 -VASc ≥2. TTR was calculated according to Rosendaal interpolation method. 13 INRs considered for TTR calculation were performed at baseline and at every subsequent follow-up visits (1 month, 3 months, 6 months, 12 months). Baseline INR range was 2.0-3.0 in 456 out of 470 patients (97.0%), while 6 patients were in the lower range (INR b2.0) and 8 patients were in the higher range (INR N3.0). Effective anticoagulation control using VKA was defined as a TTR N70%.
14 To fulfill the aims of this study we performed two distinct analyses: first, we evaluated the "dose-effect" response between progressively higher TTR tertiles and the occurrence of outcomes. Second, we evaluated the effect of having best quality anticoagulation control (i.e. the highest TTR tertile, compared to others) in relation to major adverse events. Last, we tested the relationship between effective anticoagulation control (ie, TTR N70%) and major adverse events in a sensitivity analysis.
Based on the original protocol, the principal safety outcomes were 'major bleeding', defined as intracranial, bleeding requiring blood transfusion or surgical/endoscopic treatment or leading to long-term disability or death, and 'clinically relevant non-major bleeding' (CRNMB), which was bleeding requiring no treatment or leading to ambulatory management with no surgical/endoscopic treatment.
Furthermore, the principal efficacy outcome was a composite of major acute cardiovascular/cerebrovascular events (MACCE), including acute MI, target vessel revascularization, stroke/transient ischemic attack (TIA), systemic embolic event, stent thrombosis and cardiovascular death. Acute MI was defined according to the universal definition in use at the time of the study. 15 Target vessel revascularization was defined as PCI-S or coronary bypass surgery in the previously treated vessel. Stent thrombosis was defined according to the Academic Research Consortium classification and included definite and probable events. 16 TIA was defined as a focal, transient (b24 hours) neurological deficit adjudicated by a neurologist, whereas stroke was defined as a permanent, focal, neurological deficit adjudicated by a neurologist and confirmed by computed tomography/ magnetic resonance imaging. Systemic embolism was defined as signs/symptoms of peripheral ischemia associated or not with a positive imaging test. Cardiovascular death was defined as a death related to cardiac cause or stroke.
Statistical analysis
Patients were categorized according to TTR tertiles, defined as follows: 1st Tertile (T1) b56.8%; 2nd Tertile (T2) 56.9-93.8%; 3rd Tertile (T3) N93.9%. Continuous variables were reported as median [IQR] and differences between subgroups were assessed with Kruskal-Wallis 1-way ANOVA test. Categorical variables, expressed as counts and percentages, were analyzed by chi-squared test, with Bonferroni correction for evaluation of pairwise comparisons between groups.
Differences in survival were analyzed using the log-rank test and Kaplan-Meier analysis according to TTR tertiles and, additionally, comparing patients in T3 to those in the other two tertiles combined. In order to establish if TTR was independently associated with major bleeding and MACCE a Cox proportional-hazards analysis, adjusted for age, gender, AF type, CHA 2 DS 2 -VASc score, PCI-S clinical indication and PCI-S clinical setting for both outcomes, was performed. Two distinct models were performed using TTR tertiles, both comparing T1, T2, and T3 distinctly, and secondly, comparing T3 to the other two tertiles. Furthermore, we constructed a third model using TTR as a continuous variable. A 2-sided P b .05 was considered statistically significant. In the additional sensitivity analysis, a similar analytical approach was followed using the log-rank test and Kaplan-Meier analysis for TTR N70%, followed by Cox proportional-hazards analysis using the same adjustments. All analyses were performed using SPSS v. 22.0 (IBM, New York, NY).
Results
Of the 963 patients originally enrolled in the AFCAS study, 470 (48.8%) patients were eligible for this ancillary analysis. These patients subdivided according to TTR tertiles were as follows: 145 (30.8%) in T1; 149 (31.7%) in T2; 176 (37.4%) in T3. As expected, median TTR values across tertiles progressively increased [ Figure 1 ].
Baseline characteristics according to TTR tertiles are shown in Table I . Patients in the three TTR tertiles did not show significant differences in the baseline characteristics except for the prevalence of diabetes mellitus, higher in T1 compared to T2 and T3 (P = .034). Previous gastrointestinal bleeding was more prevalent in T2 patients (P = .030). Femoral vascular access was progressively less prevalent from patients in T1 to T3 (P = .006).
Follow-up and survival analysis
After a median [IQR] follow-up of 359 [341-370] days, a total of 26 (5.5%) major bleeding and 58 (12.3%) CRNMB events occurred, while 82 (17.4%) MACCE were recorded. At 12-months follow-up, 52 (11.1%) patients were still on triple therapy; no significant differences were found between the three tertiles (data not shown).
Outcomes according to TTR tertiles are shown in Table II . Major bleeding rate progressively decreased from T1 to T3 patients (P = .006). For MACCE, patients in T2 reported the highest event rate (21.5%), while patients in T3 reported the lowest rate of MACCE (11.9%); this difference was not statistically significant (P = .066).
Survival analysis found a progressive decrease in cumulative risk for major bleeding across the three TTR tertiles (log-rank: 10 A multivariable Cox regression analysis (Table III) showed that both T2 and T3 tertiles were inversely associated with major bleeding (P = .050 and P = .005, respectively). Model 2 confirmed that the best anticoagulation control (T3) had the lowest risk for major bleeding (P = .027). The third Cox model, with TTR as a continuous variable, showed that TTR was inversely associated with major bleeding (P b .001).
For MACCE, the Model 1 adjusted Cox analysis found a non-significant lower risk for patients in T3 (P = .128). In Model 2, obtaining the best anticoagulation control was inversely associated with MACCE events occurrence (T3 vs. T1/T2, P = .033). The final model with continuous TTR showed a non-significant trend for an inverse relationship with MACCE (P = .069).
Sensitivity analysis
We performed a sensitivity analysis taking the TTR N70% cut-off as reference (Supplementary Materials). Major bleeding was significantly lower in patients with TTR N70% compared to those with TTR ≤70% (2.2% vs. 10.0%, respectively; P b .001). There was a non-significant trend for lower MACCE events (14.1% vs. 20.5%, respectively; P = .065) (Table S1 ). Kaplan-Meier curves [Figs. S2-S3] confirmed a significantly lower risk for major bleeding with TTR N70% [Fig. S2 ]. Cox regression analysis (Table S2) found that TTR N70% was independently associated with a lower risk for major bleeding (P b .001).
Discussion
In our study of AF patients undergoing a PCI-S procedure prescribed with TAT, our principal finding is that good anticoagulation control in VKA users, as reflected by a high TTR, was inversely associated with both major bleeding and MACCE. Specifically, we show a progressive stepwise risk reduction for major bleeding when going from lowest to higher TTR tertiles. Similarly, patients with the best anticoagulation control had the lowest risk of major bleeding compared to all the other patients. As far as we are aware, we provide the first data relating major bleeding to TTR in the setting of PCI-S and AF.
Several studies have shown that AF patients prescribed TAT have a higher risk for major bleeding. In a large cohort derived from the Danish nationwide cohort study, patients on TAT had almost four-fold higher risk for the composite of major fatal and non-fatal bleeding (hazard ratio [HR]: 3.70, 95% confidence interval [CI]: 2.89-4.76), with no reduction in stroke occurrence (HR: 1.45, 95% CI: 0.84-2.52). 4 More recently, a the Get-With-The-Guidelines program reported an increased risk for bleeding-related hospitalizations for AF patients prescribed TAT, with a 2-fold increased risk of intracranial hemorrhage-related hospitalizations (HR: 2.04, 95% CI: 1.25-3.34). 17 No difference was found in efficacy outcomes when comparing TAT patients with those prescribed dual antiplatelet therapy. 17 Other registry evidence has confirmed a higher risk of bleeding associated with TAT, with up to a 2-fold higher risk for any bleeding (HR: 2.08, 95% CI: 1.64-2.65), with a higher short-term risk, as well as a significant association with fatal bleeding at 30 days after discharge (HR: 1.85, 95% CI: 1.27-2.70) 5 ; however, there was also a significant reduction in ischemic stroke (HR: 0.67, 95% CI: 0.46-0.98), all-cause death (HR: 0.61, 95% CI: 0.47-0.77) and the composite outcomes for AF patients treated with TAT. 5 Similar data have been reported in elderly patients, with a 5-fold increased risk for major bleeding, with concomitant reductions of thromboembolic events and all-cause death. 18 However, all these registry studies do not provide data in relation to TTR.
In this context, our data show how the risk of bleeding during TAT is dependent on the quality of anticoagulation control, as reflected by the TTR.
Despite being inconclusive for MACCE, our data are suggestive of the importance of the quality of anticoagulation control in obtaining improved outcomes.
19-21 Our 3 tertiles were mostly comparable in clinical characteristics; additional residual confounders could have influenced the increased rate of MACCE for patients in T2, beyond the quality of anticoagulation control. Nevertheless, patients in T3 had the lowest rate of MACCE events suggesting that better control of TTR may lower the risk. Larger prospective studies would be needed to confirm these trends.
Several published studies have reported how TTR is a strong predictor of both thromboembolic-related and bleeding-related outcomes, independent from body weight, 22 renal function, 23 and gender. 24 Moreover, the importance of anticoagulation control in properly evaluating potential bleeding risk has been recently shown. 25, 26 In a large systematic review, Wan et al. clearly show an inverse linear association between TTR and outcomes, both bleeding and thromboembolic. 9 More recently, a large observational study confirmed the inverse relationship between TTR and adverse outcomes. 27 The joint European consensus document recommends evaluation of the balance between thromboembolic and bleeding risks, then minimizing the period of TAT treatment to 4 weeks in patients with a high risk of bleeding (HAS-BLED ≥3), followed by 12 months of single antiplatelet therapy with clopidogrel and OAC, either with a VKA (e.g. warfarin) or non-vitamin K antagonist oral anticoagulant (NOAC). 8 For VKA therapy, a narrower therapeutic range is recommended (INR 2.0-2.5) and for NOACs, the lower approved dose for stroke prevention in AF should be used. 8 In the WOEST trial, clopidogrel plus warfarin was associated with a reduced risk of any bleeding (largely driven by reduction in minor bleeds) compared to TAT without any increase in thrombotic events. 28 Despite that, WOEST did not provide any data in relation to TTR. Our results substantiate the recommendations in the European consensus document on maintaining optimal anticoagulation control while taking VKA.
Recently, results from the PIONEER AF-PCI study 29 showed that the two arms with different rivaroxaban doses, 15 mg and 2.5 mg, resulted in a significantly lower 30 Despite a significant reduction of recurrent hospitalization (particularly those related to bleeding and cardiovascular reasons), 31 this study did not show significant reduction in all major adverse cardiovascular events, due to limited power. 30 The overall TTR recorded for the VKA arm was 65%, but the use of NOACs in this setting seems encouraging. Several ongoing randomized clinical trials would provide additional evidence. 32 
Limitations
The main limitation of this study is the post-hoc subgroup retrospective design, which was not powered to detect differences in the specified subgroups, warranting further confirmation from adequately powered prospective studies. Even if the groups considered were comparable according to the baseline characteristics, the presence of additional confounders cannot be completely excluded and fully accounted for. Also, the limited number of patients still on TAT at 1-year follow-up would represent another limitation. Nonetheless, we still show important associations particularly for bleeding events, in relation to tertiles of TTR. Some suggestive trends for an inverse relationship between TTR and MACCE, but our data do not allow us to draw definite conclusions, requiring further adequately powered studies to confirm this aspect.
In conclusion, in AF patients undergoing a PCI-S prescribed TAT, good quality anticoagulation control (as reflected by TTR) was closely related to better bleeding outcomes during follow-up. Despite some suggestive trends for an inverse relationship between TTR and MACCE, no definitive conclusions can be drawn, and further large studies are needed. Kaplan-Meier curves for major adverse events according to TTR tertiles. MACCE, major adverse cardiac/cerebrovascular events. 
